Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin, is a ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia^[2]. In Vitro: Taribavirin (0-2 μM; 24 hours) significantly induces MCF-7 cell death, recording half inhibitory effect (IC₅₀) of 0.756 μM in MCF-7 cells^[1].